Vivus' impotence therapy granted US patent:
This article was originally published in Clinica
Vivus has received a US patent for its MUSE drug delivery system for treating erectile dysfunction. The non-invasive system delivers alprostadil, a vasodilator, via the urethra to increase blood flow to the penis and maintain functional blood vessels within the organ. Earlier this year, Vivus, of Mountain View, California, saw sales of its device plunge by 70% as a result of the launch of Pfizer's pharmaceutical, Viagra (see Clinica No 816, p 9).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.